Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 4/20 | 0.48 |
| ▸ | FPR2 | P25090 | 4/20 | 0.48 |
| ▸ | DPP4 | P27487 | 5/20 | 0.48 |
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21144761 | 1.00 | FPR1 (0.48) | FPR1FPR2DPP4ACACBDPP8 | |
| SCHEMBL21144696 | 0.90 | DPP4 (0.46) | FPR1FPR2DPP4ACACBCTSC | |
| SCHEMBL21144739 | 0.90 | DPP4 (0.46) | FPR1FPR2DPP4ACACBKCNH2 | |
| SCHEMBL21144694 | 0.90 | DPP4 (0.46) | FPR1FPR2DPP4ACACBCTSC | |
| SCHEMBL21144741 | 0.90 | DPP4 (0.46) | FPR1FPR2DPP4ACACBKCNH2 | |
| SCHEMBL18930496 | 0.83 | FPR1 (0.43) | FPR1FPR2DPP4 | |
| SCHEMBL21144957 | 0.82 | FPR1 (0.45) | FPR1FPR2DPP4ACACBDPP8 | |
| SCHEMBL21144956 | 0.82 | FPR1 (0.45) | FPR1FPR2DPP4ACACBDPP8 | |
| SCHEMBL21144965 | 0.80 | DPP4 (0.72) | FPR1FPR2DPP4DPP8FAP | |
| SCHEMBL21144962 | 0.80 | DPP4 (0.72) | FPR1FPR2DPP4DPP8FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-19 | — | — | US | disclosed |
| EP-3383865-B1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | Bayer Pharma AG (DE) | 2020-01-29 | — | — | EP | disclosed |
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | ATAD2, ATAD2B, TAF1L | FPR1 2439/4885FPR2 2431/4885DPP4 3896/4885 |
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | ATAD2, ATAD2B, TAF1L | FPR1 2439/4885FPR2 2431/4885DPP4 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.